Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Endo Appoints Corporate Development VP | Contract Pharma
Breaking News, Promotions & Moves

Endo Appoints Corporate Development VP

Valeant veteran brings specialty pharma experience

Hemanth J. Varghese, Ph.D., CFA, has been appointed executive vice president of corporate development and strategy at Endo International. Dr. Robert Cobuzzi, who previously served in this role will now serve as senior vice president, U.S. branded pharmaceuticals R&D strategy and operations. Dr. Varghese will report to Rajiv De Silva, Endo’s president and chief executive officer.
 
Dr. Varghese brings corporate development and general management experience in specialty pharmaceuticals, most recently serving as senior vice president and general manager vision care for Bausch & Lomb, a division of Valeant Pharmaceuticals. Dr. Varghese also held senior leadership roles at Valeant, including senior vice president of corporate development and general manager of Valeant’s Neurology & Other business unit.
 
“We are excited to announce the addition of Hemanth to the Endo executive team. His accomplishments and experience in corporate development and integrations will allow us to accelerate the execution of our strategy as we continue to expand our business through value creating acquisitions and partnerships,” said Mr. De Silva. “Hemanth’s track record of success will play a significant role as we execute against our strategy to become a leading specialty healthcare company.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters